Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether metformin, an FDA-approved drug for the
treatment of type II diabetes, is a safe and effective treatment to decrease the progression
of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
California Retina Consultants Northwestern University Oregon Health and Science University Retina Health Center Retinal Consultants Medical Group San Francisco Veterans Affairs Medical Center University of California, Davis University of California, Irvine University of California, Los Angeles University of California, San Diego University of Illinois at Chicago VA Palo Alto Health Care System